Genomic Health

Exactis is committed to conducting its activities with the highest ethical and professional standards to ensure respectful treatment of patients and all stakeholders, this includes respecting the rights and privacy of patients, ethical standards, and regulatory requirements. Exactis Innovation (Exactis) is a Canadian not-for-profit focused on improving cancer survivorship by empowering the healthcare ecosystem to make more timely data-driven decisions through real-world data. Together, we are working towards better patient outcomes, longer lives, and a more efficient healthcare system. Our REB-approved Databank and clinical network make us a trusted Canadian partner for oncology real-world evidence (RWE) studies. We believe everyone has a role to play in fighting cancer.This is ours.

We are driven forward by a vision of a future where cancer is curable. We are developing blood tests that detect cancer in its earliest stages so we can transform cancer into a disease that’s preventable and curable. We are applying our multi-omics, computational biology and machine learning approach to capture cancer’s signal for high-burden gastrointestinal cancers. Starting with colorectal cancer, we are building a multi-cancer platform that can identify the unique DNA regions associated with different types of cancers. Cancer’s early detection has become one of the greatest challenges of modern medicine, so we decided to team up with the best. Our company was founded on Silicon Valley’s ideals of technology and development (Singularity University), and we developed a network of world-class R&D partners including Quest Diagnostics and Hologic (Diagenode). Our Scientific Advisory Board includes leading oncologists, gastroenterologists and business experts from the US and Europe. We have built a network of >100 hospitals in the U.S.

We are experts in developing and providing personalised cancer genetics tests for doctors and patients, and testing tumours for sensitivity and resistance to chemotherapy treatment and a range of natural substances. We encourage imaginative thinking to explore, question and reinvent, creating products, systems and technologies to challenge expectations. Working in the field of advanced medical genetics, our team of scientists and medical experts have developed a range of reliable tests so patients and clinicians can make informed decisions about healthcare. This is why we’re focused on creating modern and innovative products that will have a positive impact on day-to-day living.

We aren't just your testing lab — we are here to support throughout your whole research to CDx journey. That discovery ignited our mission to leverage liquid insights in the body to transform research on a more personal, individual level. Located on the Johns Hopkins Medical Campus, we have played a leading role in the fight against cancers since our inception in 2008 and as a CLIA lab for the last 10 years. We believe each of us has a unique story to tell, so we test to track every molecule, changing outcomes for the better.

As a premiere molecular health laboratory, we harness cutting-edge technologies and expertise to deliver precise and actionable insights. Our team of scientists and healthcare professionals strives to provide accurate diagnoses and personalized treatment options, empowering individuals to make informed decisions about their health. At Advanced Clinical Solutions, we’re not just service providers – we’re your partners in care.

At any stage of care, we provide actionable results tailored to each patient. No matter where your patient is with their cancer, Precision Oncology provides earlier detection and smarter answers. By delivering precise information about what’s in an individual’s tumor profile, it helps you show your patient what is and put an end to the “what ifs.”. The Oncotype DX® tests deliver clinically relevant genomic intelligence specific to the individual biology of a patient’s tumor—equipping physicians with the Exact insights they need. The OncoExTra™ test delivers rapid and comprehensive tumor profiling that aids therapy selection for patients with advanced or metastatic cancer—utilizing a complete biological picture to match their needs. That’s why we offer the Genomic Access Program (GAP) to help patients navigate the insurance and billing process.